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Abstract  
Background:  Fragile X Syndrome (FXS), a neurodevelopmental disorder, is a leading monogenetic cause 
of intellectual disability and autism spectrum disorder.  Notwithstanding the extensive studies using 
rodent and other pre-clinical models of FXS, which have provided detailed mechanistic insights into the 
pathophysiology of this disorder, it is only relatively recently that human stem cell-derived neurons have 
been employed as a model system to further our understanding of the pathophysiological events that 
may underlie FXS.  Our study assesses the physiological properties of human pluripotent stem cell-derived 
cortical neurons lacking fragile X mental retardation protein (FMRP). 
Methods:  Electrophysiological whole-cell voltage- and current-clamp recordings were performed on two 
control and three FXS patient lines of human cortical neurons derived from induced pluripotent stem cells.  
In addition we also describe the properties of an isogenic pair of lines in one of which FMR1 gene 
expression has been silenced. 
Results:  Neurons lacking FMRP displayed bursts of spontaneous action potential firing that were more 
frequent but shorter in duration compared to those recorded from neurons expressing FMRP.  Inhibition 
of large conductance Ca2+-activated K+ currents and the persistent Na+ current in control neurons 
phenocopies action potential bursting observed in neurons lacking FMRP, while in neurons lacking FMRP 
pharmacological potentiation of voltage-dependent Na+ channels phenocopies action potential bursting 
observed in control neurons.  Notwithstanding the changes in spontaneous action potential firing, we did 
not observe any  differences in the intrinsic properties of neurons in any of the lines examined.  Moreover,  
we did not detect any differences in the properites of miniature excitatory postsynaptic currents in any of 
the lines.  
Conclusions:  Pharmacological manipulations can alter the action potentials burst profiles in both control 
and FMRP-null human cortical neurons, making them appear like their genetic counterpart.  Our studies 
indicate that FMRP targets that have been found in rodent models of FXS are also potential targets in a 
human-based model system and we suggest potential mechanisms by which activity is altered.   
Keywords: fragile x syndrome, disease-modelling, electrophysiology, action potential 
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Background  
Fragile X Syndrome (FXS) is a leading genetic cause of intellectual disability and one of the most common 
monogenic causes of autism spectrum disorder. FXS results from the loss of expression of FMRP, the 
protein produced from the FMR1 gene.  As the FMR1 gene is located on the X chromosome, FXS occurs 
more in males (1:4,000) than in females (1:6,000 – 8,000) [1, 2].    Individuals with FXS exhibit a variety of 
symptoms – learning disabilities, anxiety, unstable mood, attention deficit, hyperactivity, seizures and 
altered social behavior [3-5].  Extensive mechanisitic studies in rodent models of FXS have shown that 
FMRP is a mRNA translational repressor [6] and a key feature found in pre-clinical models of FXS is 
dysregulation of protein homeostasis [7].  Furthermore, many of the proteins that are targets of FMRP 
are found at central synapses and/or influence neuronal excitability [8].  Indeed a distinguishing feature 
in rodent models of FXS, is altered neuronal integration of excitatory and inhibitory inputs and 
concomitant aberrant network activity [9-14].  Indeed, perturbation of the neuronal circuits and networks 
in the early stages of brain development are likely to be responsible for many of the impairments exhibited 
by individuals with a range of neurodevelopmental disorders.  However, it is not always the case that all 
neuronal populations show hyperexcitability; a recent study using mouse primary cortical neurons 
demonstrated that loss of FMRP did not affect the basal neuronal excitability [15] while a study using fetal 
rat visual cortex showed the Fmr1 null neurons to be hypoexcitable [16]. Indeed, such results which may 
be taken by some to be conflicting but equally could simply illustrate the complexity of studying FXS 
pathophysiology in rodent models.   
While the extensive studies using rodent and other pre-clinical models of FXS have provided detailed 
mechanistic insights into the pathophysiology of this disorder, it is only relatively recently that human 
stem cell-derived neurons have been employed as a model system to further our understanding of the 
pathophysiological events that may underlie FXS [17-19].  To date, there have been relatively few studies 
that have examined the effects of loss of expression of FMRP in human neurons in the context of cellular 
excitability and network function [20-23].  Despite the paucity of such studies, there are differences 
reported in whether human FMR1 null neurons display hypo- [21] or hyper- [23] activity.  Furthermore, it 
is imperative that we assess whether key cellular phenotypes, first decribed in animal models of FXS, are 
present in human-derived cells.  Moreover, potential therapeutic interventions developed from such pre-
clinical studies have, to date, not been successful in developing treatments and as such the need for 
functional assessment in a ‘human-based’ platform offers the opportunity to expand our understanding 
of dysregulated signalling. Thus, not only are such studies essential to identify any species differences and 
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to translational understanding of FXS, they can also provide a ‘human-based’ platform to assess potential 
therapeutics.   
 Given the large number of FMRP targets that are associated with synaptic function and the well-
described synaptic and network properties that are dysregulated in pre-clincal models of FXS our present 
study focuses on assessing the physiological properties of two control (CON1, CON2) and three FXS patient 
lines (FXS1, FXS2, FXS3) of human cortical neurons derived from induced pluripotent stem cells (iPSCs).  In 
addition, to ensure that the differences we observe in FXS patient lines are due to the sliencing of the 
FMR1 gene and the absence of FMRP and not differences in the different genetic backgrounds or 
‘environmental’ influences on the iPSC-derived neurons we also describe the properties of an isogenic 
pair of lines [24], one of which has had the FMR1 gene genetically deleted (FMR1-/y) to allow direct 
comparison with an otherwise genetically identical line (FMR1+/y).  Using electrophysiological recordings 
we report that there is altered spontaneous neuronal action potential burst firing activity in all lines that 
lack FMRP.  This occurs in the absence of differences in either intrinsic or synaptic properties in each of 
the lines, whether they express FMRP or not.  We demonstrate through pharmacological approaches how 
this spontaneous action potential firing can be manipulated in order to understand the mechanistic basis 
underlying the dysregulated activity exhibited in neurons lacking FMRP.  
Materials and Methods 
Generation of primary rodent astrocytes 
Primary rodent astrocytes were isolated from the cerebral cortex of E18.5 CD 1 mice as described 
elsewhere [25]. Briefly, cortices were dissected, enzymatically digested and mechanically dissociated. 
Astrocytes were plated on poly-D-lysine and laminin (Sigma) coated plates in medium containing DMEM 
supplemented with 10% FBS (Thermo Fisher Scientific) and passaged twice prior to co-culturing with 
neurons on a 24 well- plate. For co-cultures, human NPCs (30,000 cells/cover-slip) were plated on to a 
layer of astrocytes and differentiated into neurons in a humidified incubator (5% CO2) at 37°C for 8 weeks. 
hiPSC and hESC lines 
SC176 (apparently healthy control male) and SC128 (fragile X syndrome male) fibroblasts and hereafter 
referred to as CON1 and FXS1 lines, respectively, were obtained from Dr. Philip H. Schwartz at Children’s 
Hospital of Orange County’s National Human Neural Stem Cell Resource (http://nhnscr.org/). Fibroblast 
lines were reprogrammed at the Laboratory for Translational Cell Biology at Emory University (Atlanta, 
GA) using established protocols and under institutional approval.  Induced human pluripotent stem cells 
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(hiPSCs) were generated by transducing control and FXS patient fibroblasts with Sendai virus from the 
Cytotune 2.0 Reprogramming Kit (Thermo Fisher Scientific, Waltham, MA) as per the manufacturer’s 
protocol.  Briefly, early passage fibroblasts were cultured in fibroblast medium (10% ES-qualified FBS, 0.1 
mM NEAA, 55 µM β-mercaptoethanol, high glucose DMEM with Glutamax) for two days. On day 0, 
fibroblasts were transduced with Sendai virus cocktail of KOS, hc-Myc, hKlf4. Cells were fed with fibroblast 
medium every other day for one week.  On day 7, cells were passaged onto vitronectin (Thermo Fisher 
Scientific) coated dishes at a density of 250,000 to 500,000 cells/well.  Beginning on day 8, cells were fed 
every day and colonies began to emerge within another 7-10 days.  Individual hiPSC colonies were 
manually picked and transferred to a dish coated with either vitronectin or Matrigel (BD Biosciences, San 
Jose, CA) and expanded as clonal lines. hiPSCs were maintained on Matrigel coated dishes and fed every 
day with complete mTesR1 medium (Stem Cell Technologies).  hiPSCs were passaged every 5-7 days using 
ReLeSR (Stem Cell Technologies, Cambridge, MA).  ND30625 (apparently healthy control male), GM07072 
(fragile X syndrome male) and GM05848 (fragile X syndrome male) fibroblasts and hereafter referred to 
as CON2, FXS2 and FXS3 lines, respectively, were obtained from the Coriell Institute of Medical Research 
under their consent and privacy guidelines as described on their website (http://catalog.coriell.org/). 
hiPSC generation was carried out at Cedars-Sinai Medical Centre (Los Angeles, CA).  Fibroblasts were re-
programmed into non-integrating and virus-free hiPSC by nucleofecting episomal plasmids expressing the 
reprogramming factors OCT4, SOX2, KLF4, L-MYC, LIN28 and shRNA to TP53.  All newly reprogrammed 
hiPSC lines were confirmed to have normal karyotypes and passed a battery of characterization tests for 
pluripotency including hiPSC Scorecard Assay, PluriTest, and RT-qPCR to confirm endogenous expression 
of pluripotency and confirm the lack of exogenous gene expression. The reprogrammed iPSC lines were 
also authenticated by matching the identity to the parental fibroblast sample by short tandem repeat 
(STR) profiling and compared to parental tissue source (fibroblasts). For STR profiling, the iPSC lines were 
authenticated by contracting with IDEXX Laboratories, Inc. and use of their CellCheck 9 service. All hiPSC 
lines were regularly karyotyped (WiCell, Madison, WI) and characterized for expression of markers of 
pluripotency using immunofluorescence and RT-PCR.   The human embryonic stem cell (hESC) line Shef 4, 
hereafter referred to as FMR1+/y, was obtained from UK Stem Cell Bank [26]. The Shef 4 FMR1 null line, 
hereafter referred to as FMR1-/y, was generated using CRISPR-Cas9 technology as described previously 
[24].  hiPSC and hESC colonies were cultured and propagated in xeno-free and feeder free conditions using 
Essential 8 medium (Thermo Fisher Scientific) in 6 well plates (Nunc Nunclon delta surface, Thermo Fisher 
Scientific) coated with reduced growth-factor Matrigel (Corning Inc, New York, NY) at 37°C, 5% CO2 in a 
humidified incubator. The colonies were cultured to 90% confluence and enzymatically passaged for 
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further propagation and cryopreservation [27].  Each of the cell lines used in this study are listed in Table 
1; all experiments were performed after obtaining statutory institutional ethical clearances. 
ID in 
manuscript 
ID at source Age  
(years) 
Sex Reprogrammed  
cell line name 
Re-programming 
method 
Starting 
cell type 
G band 
karyotype 
CON1 SC176 14 M SC176  Sendai virus Fibroblast Normal 
CON2 ND30625 76 M CS25iCTR-18nxx Episomal vectors Fibroblast Normal 
FXS1 SC128 23 M SC128 Sendai virus Fibroblast Normal 
FXS2 GM07072 22 M CS072iFXS-n4 Episomal vectors Fibroblast Normal 
FXS3 GM05848 4 M CS8488iFXS-n5 Episomal vectors Fibroblast Normal 
FMR1+/y SHEF 4 ESC M NA NA - Normal 
FMR1-/y SHEF 4-FMR1 null ESC M ESC- CRISPR Cas 9 
edited 
NA - Normal 
 
Table 1.  Details of cell lines used in this study. 
Generation and expansion of cortical NPCs and neural differentiation 
Cortical NPCs were derived from each of the cell lines mentioned above as described previously.  Similarly, 
cryopreservation, maintenance, characterization and expansion of cortical NPCs was carried out according 
to previously published protocol [27].  Human cortical neurons were differentiated from cortical neural 
precursor cells as described earlier [27]. Briefly, cNPCs were plated on to 13 mm glass coverslips (VWR, 
Radnor, PA) coated with poly-L-ornithine, laminin, fibronectin (Sigma, St. Louis, MO) and reduced growth-
factor Matrigel  at 30,000 cells / coverslip in default medium; maintained at 3% O2, 5% CO2, 37°C for 1 
week (days 1-7) followed by default medium with forskolin (Tocris Bioscience, Bristol, UK) for further 2 
weeks (days 8-21) and supplemented with BDNF and GDNF (R&D Systems, Minneapolis, MN) for 5 weeks 
(days 22-56).  Immunostaining and electrophysiological characterization was performed at the end of 8 
weeks. 
Western blot analysis 
hiPSC and hESC pellets were lysed using lysis buffer (50 mM Tris-HCL, pH 7.4, 2mM EDTA, 0.1% SDS, 1% 
Triton-X 100, 0.5% Na-deoxycholate, 150 mM NaCl, Protease and Phosphatase inhibitor cocktails) 
sonicated (10 cycles of 30s on/30s off) and centrifuged at 13,000 RPM for 10 min. The supernatant was 
collected and protein estimation performed using BCA assay kit (Thermo Fisher Scientific). 20 µg/sample 
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protein was loaded on a precast NuPAGE 4-12% Bis-Tris Protein gel (Thermo Fisher Scientific) followed by 
protein transfer to a PVDF membrane (GE Healthcare, Life science, Chicago, IL). The blot was blocked in 
1:1 TBST (0.2 M Trizma base, 0.15 M NaCl, 0.1% Tween-20) and Odyssey blocking buffer (Li-COR 
Bioscience, Lincoln, NE) for 1 hour at room temperature. The membrane was incubated with primary 
antibodies FMRP (1:1000, AbCam, Cambridge, UK) and β-actin (1:5000, Sigma), in blocking buffer for 
overnight at 40C; washed with TBST and incubated in secondary antibodies with IRDye 680RD and IRDye 
800CW (Li-COR Bioscience) respectively for 1 hour at room temperature.  Following further washing, the 
blot was dried and imaged using Li-COR Odyssey FC infrared system. 
Immunocytochemistry and imaging 
hiPSCs, hESCs, NPCs and neurons were stained as per standard immunocytochemistry protocols. Briefly, 
cells were fixed with 4% PFA for 10 minutes followed by permeabilisation for 5 minutes using 0.3% Triton 
X (USB Corporation, Cleveland, Ohio, OH). Cells were incubated in 3% BSA (Sigma) for 30 minutes to block 
non-specific binding of antibodies. Further, cells were incubated in primary antibody at room temperature 
and secondary antibody consecutively for 1 hour each, mounted onto glass slides using Fluorsave (Sigma) 
and stored at 4°C in the dark till imaging.  Images were acquired using a confocal laser scanning 
microscope (Fluoview 3000 Olympus, Japan). hiPSCs, ESC imaging was done using a 40X (1.3 NA) oil 
immersion objective, NPCs and co-culture images were captured using 60X (1.4 NA) oil immersion 
objective with diode lasers 405 nm, 488 nm, 561 nm and 640 nm. All images were captured at 512 x 512 
pixels per inch; Z step size was set at 0.5 µm with 1 airy unit of pinhole diameter. 
Electrophysiology 
Electrophysiological recordings were made at room temperature (23 – 24°C) and similar protocols to those 
described previously [27-29] were used.  Coverslips, containing human cortical neurons that had been 
cultured for 8 weeks, were transferred to a recording chamber and whole-cell current- or voltage-clamp 
recordings were made using a Molecular Devices MultiClamp 700B amplifier (Molecular Devices, San Jose, 
CA).  Cells were perfused with an external recording solution comprising of (in mM):  NaCl 152, KCl 2.8, 
HEPES 10, CaCl2 2, glucose 10, pH 7.3 – 7.4 (300 – 320 mOsm) with a flow rate of approximately 1.35 ml 
per minute.   
For current-clamp recordings patch-pipettes, fabricated from thick-walled borosilicate glass, were filled 
with an internal recording solution containing (in mM): K-gluconate 155, MgCl2 2, HEPES 10, Na-PiCreatine 
10, Mg2-ATP 2 and Na3-GTP 0.3, pH 7.3 (280 - 290 mOsm) and had resistances of 3-4 MΩ.  The liquid 
junction potential was calculated to be +14 mV (JPCalc, Clampex) and the values for membrane potential 
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reported here do not take liquid junction potential into consideration.  For the assessment of intrinsic 
membrane properties and recording of spontaneous network activity, current-clamp recordings were 
performed at a potential of –60 mV with bridge balance mode and pipette capacitance neutralised.  The 
duration of action potential bursts were measured from the start of the first action potential to the time 
of the last action potential with bursts being defined as two or more action potentials occurring during a 
period of depolarization.  Data were filtered at either 3 kHz or 10 kHz, for voltage-clamp and current-
clamp recordings, respectively, and digitized, via a Digidata 1550, at 20 kHz.  Stimulation protocols were 
generated using pClamp 10.5 software and subsequent offline analysis was conducted using Clampfit 10.5 
software.   
For voltage-clamp recording patch-pipettes were filled with an internal solution consisting of (in mM): Cs-
gluconate 110, CsCl 20, HEPES 10, NaCl 4, QX-314 5, EGTA 0.2, Na-PiCreatine 10, Mg2-ATP 2 and Na3-GTP 
0.3, pH 7.3 (280 - 290 mOsm) and neurons were clamped at –70 mV.  Where recordings of miniature 
excitatory postsynaptic currents (mEPSCs) were performed the external recording solution was 
supplemented with tetrodotoxin (TTX; 500 nM) and MgCl2 (1.3 mM) to block the NMDA receptor-
component of synaptic events.  To record the persistent sodium current (INaP), neurons were clamped at 
–80 mV, then stepped to –100 mV and a depolarizing voltage ramp [30] to –20 mV (20 mV/s) was applied.  
INaP was isolated by subtracting the current recorded in the presence of TTX (1 µM) from current recorded 
immediately prior in the same neuron but in the absence of TTX.  To record the Ca2+-activated BK current 
(IBKCa), neurons were clamped at –60 mV, then stepped to –110 mV and a depolarizing voltage ramp [31] 
to +40 mV (100 mV/s) was applied, with neurons being held at +40 mV for a further 50 ms.  During these 
recordings the external recording solution was supplemented with TTX (0.5 µM) and with IBKCa being 
isolated by subtracting the current recorded in the presence of paxilline (10 µM) from current recorded 
immediately prior in the same neuron but in the absence of paxilline.  
Statistical Analysis 
All values are expressed as mean ± standard error of the mean (SEM) and each data set was assessed for 
normality.  For the analysis of intrinsic membrane properties, mEPSC and network recordings, one-way 
repeated analysis of variance (ANOVA) followed by post-hoc Tukey’s test was used. Paired statistical tests 
were used for data sets before and after drug application. Paired t-test was used for data sets that passed 
the normality test, and Wilcoxon test was used for data sets that failed the normality test.  Two –way 
repeated measures ANOVA, followed by post-hoc Tukey’s test was used for INaP and IBKCa current – voltage 
relationships.  All statistical tests were performed using GraphPad Prism (GraphPad software Inc., La Jolla, 
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CA, RRID: SCR_002798).  The number of experimental replicates (cells) is denoted as ‘n,’ while ‘N’ 
represents number of de novo preparations of batches from which ‘n’ is obtained. 
Results 
Absence of FMRP does not affect differentiation efficiency of FMRP-lacking neurons. 
Fibroblast derived iPSCs were generated from two healthy individuals (CON1 and CON2), three FXS 
patients lacking FMRP (FXS1, FXS2 and FXS3), and one isogenic embryonic stem cell (FMR1+/y; FMR1-/y) pair 
where the FMR1 gene was deleted using CRISPR/Cas9 mediated genome editing [24].  Absence of FMRP 
in FXS1, FXS2, FXS3 and FMR1-/y PSC colonies was confirmed using western blot analysis as shown in Figure 
1A (N=3).  All cell lines expressed pluripotent stem cell markers (Oct3/4 and Nanog) as shown in Figure 1B 
(left panel, N = 3; n = 9).  NPCs were generated from PSC and further terminally differentiated into neurons 
using previously published protocols [27].  Immunocytochemistry showed high expression of NPC 
markers, Nestin and PAX6  across all samples (middle panel, N = 6; n = 18).  Immuno-labelling of co-cultures 
at 8 weeks post differentiation revealed cells positive for Map2ab and human nuclear antigen (hNA) 
confirming all neurons to be of human origin only (Figure 1B right panel, N=6; n=18). Comparable 
differentiation efficiency was observed across all 7 lines. These data demonstrate that loss of FMRP does 
not affect the differentiation potential of human PSC derived cortical neurons in vitro.  
Human neurons lacking FMRP display altered spontaneous action potential burst firing 
patterns 
Recordings from principal neurons from Fmr1-/y mice have shown increased action potential bursting in 
the somatosensory cortex and hippocampus [12, 32].  Moreover, in vitro cultures of cortical neurons 
derived from human pluripotent stem cells develop synchronous burst activity [33, 34]. Thus, to assess 
the effects of the loss of FMRP on the network bursting we examined spontaneous (action potential-
driven) activity in both the isogenic hESC lines and the hiPSC lines.  Figure 2A, B illustrates that in neurons 
lacking FMRP current-clamp recordings show that the nature of bursts of action potentials are 
considerably different to those seen in neurons where FMRP is present.  In FMR1+/y, CON1 and CON2 lines 
bursts of action potentials occur at a low frequency (Fig. 2C) but have long durations (Fig. 2D) as defined 
by the interval between the first and last action potential in a burst.  In contrast, those lines lacking FMRP 
(FMR1-/y, FXS1, FXS2 and FXS3) gave rise to bursts that occurred at greater frequencies but with shorter 
durations.  While not quantified in terms of their action potential bursting patterns, evidence for increased 
frequencies of firing in iPSC-derived neurons from FXS patients has recently been reported [23]. 
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In voltage-clamp the network activity occurring in a culture could readily be identified as large 
inward currents that lasted for several seconds and which occurred at regular frequencies (Fig. 3).  As with 
the current-clamp recordings the duration of these inward currents were longer and occurred at lower 
frequencies for neurons derived from FMR1+/y and CON1 lines compared to those from FMR1-/y and FXS1 
lines (Fig. 3A, B).  Bursting activity was NMDA-receptor dependent as it was abolished by applying AP-5 to 
the external recording solution (data not shown) and as indicated by the expanded traces (Fig. 3A) result 
from the summation of many individual synaptic events impinging on a neuron simultaneously.  In the 
current-clamp recordings (Fig. 2) the synaptic events drive the waves of depolarization and result in the 
trains of action potentials that are observed.  Quantification of the number and duration of these events 
(Fig. 3C, D) revealed statistically significant differences in nature of the activity seen in FMR1+/y, CON1 and 
CON2 lines compared with those lines that lacked expression of FMRP with the duration of the voltage-
clamp recorded events matching those recorded in current-clamp.  The presence of wild-type cortical 
mouse astrocytes has been shown to rescue morphological differences observed in Fmr1-/y mouse 
hippocampal neurons [35].  However, the distinct neuronal firing profiles we report are obtained when 
human neurons expressing or lacking FMRP are co-cultured with wild-type (mouse) astrocytes.  This 
indicates that using the culture conditions employed in this study these action potential bursting 
phenotypes are cell-autonomous.  We next turned our investigation to assess whether the observed 
differences were due to either intrinsic or synaptic properties of neurons lacking FMRP.  
Despite different spontaneous action potential firing patterns, absence of FMRP in human 
cortical neurons does not alter intrinsic or synaptic properties  
Given the distinct patterns of spontaneous burst firing in neurons lacking FMRP compared to control 
neurons we sought to determine whether this was due to differences in either intrinsic or synaptic 
properties between cell lines.  Indeed, rodent models of FXS have reported that some classes of principal 
neurons lacking FMRP display altered intrinsic excitability [9, 12-14, 36] although others have not 
observed difference in these parameters [15, 37] most likely reflecting the fact that where differences do 
occur these are cell-type specific, rather than a generalised alteration in intrinsic excitability due to the 
loss of expression of FMRP.  However, human neurons lacking FMRP have been reported to exhibit a 
considerably compromised ability to generate trains of action potential firing in response to depolarizing 
current injections [21].  However, using the protocols described above to generate human excitatory 
cortical neurons we observed no differences in either passive or active membranes properties in any of 
the lines we studied (Fig. S1).   Specifically, our data do not align with this previous study [21] that reported 
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human ESC-derived neurons lacking FMRP were only capable of firing, at most, one action potential in 
response to depolarising current injections. 
To assess whether, with our protocols, loss of FMRP alters synaptic activity we recorded the 
mEPSCs from hESC- and hiPSC-derived neurons.  Previous studies of hPSC-derived cortical neurons have 
suggested that neurons lacking FMRP possess low levels of spontaneous synaptic activity [20, 21].  
Notwithstanding, the spontaneous synaptic activity as assessed by recording mEPSCs (Fig. S2A, B) 
indicated that mEPSC frequencies (Fig. S2C) and their amplitudes (Fig. S2D) were not different in neurons 
lacking FMRP compared to control.  
While we could not find differences in either intrinsic or synaptic properties between cells that 
either expressed FMRP or lacked FMRP the fundamentally different firing patterns indicates that there 
must be a differential regulation of some ionic conductances that contribute to the bursting profiles.  Thus, 
we next considered whether, through pharmacological manipulations, we could alter the nature of the 
bursting activity observed in each of the sets of cell lines. 
Neurons lacking FMRP show reduced INaP densities and their bursting properties are 
insensitive to riluzole 
Recent studies have suggested that the altered excitability of neurons lacking FMRP in a mouse model of 
FXS is due to altered persistent sodium current (INaP) activity [30, 38].  Although as indicated in Figure 2 
we do not observe different action potential firing in response to relatively brief direct depolarizing  
current injection in each of the cell lines examined it is likely that during prolonged periods of 
depolarization altered properties of intrinsic membrane currents underlie the different types of activity 
we observe.  Indeed, INaP is intimately associated with determining the properties of burst firing of neurons 
[39-43].  A slow depolarizing voltage ramp was applied to neurons and the INaP pharmacologically isolated 
by recording in the absence and presence of TTX [30, 44]. Figure 4A illustrates persistent sodium current 
recordings from FMR1+/y and FMR1-/y neurons. The magnitude of INaP in FMR1-/y and FXS3 lines is 
significantly reduced compared to those in FMR1+/y and CON2 lines.  These significant decreases in INaP are 
quantified in Fig.4B, C.  As illustrated in Fig. 4A-C the magnitude of INaP was significantly greater in FMR1+/y 
and CON2 lines than that of either FMR1-/y or FXS3 lines. 
 Given the significantly lower magnitude of INaP in neurons lacking FMRP we hypothesized that 
pharmacological block of INaP would alter the burst parameters of control neurons such that they would 
resemble the neurons lacking FMRP.  As illustrated and quantified in Fig. 4D-F the INaP blocker, riluzole (0.1 
µM) significantly reduced the duration of action potential bursts in each of the FMR1+/y and CON2 lines 
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without affecting their overall frequency thereby confirming the role of INaP in determining the action 
potential burst profile in human cortical neurons.  Moreover, riluzole had no effect on the action potential 
burst parameters in FMR1-/y and FXS3 neurons as might be expected given the low density of INaP in these 
cells.  These data are in contrast with studies using Fmr1-/y mice where it has been reported that INaP is 
enhanced in neurons lacking FMRP [30, 38]. 
In neurons lacking FMRP veratridine decreases action potential burst frequencies but 
increases their duration  
As illustrated above in the FMR1-/y and FXS3 lines the density of INaP was considerably reduced compared 
to that seen in FMR1+/y and CON2 lines.  Since INaP block does alter network properties in FMRP-containing 
neurons to resemble the bursting profile of FMRP-lacking neurons, we hypothesized that activation of 
voltage-gated Na+ channels would be able to correct the activity differences seen in FMRP null neurons.  
Indeed, the voltage-dependent Na+ channel activator, veratridine (0.5 µM), has a selective action on the 
burst firing patterns we recorded.  As illustrated in Figure 5, it had no significant effect on the burst 
parameters we measured in FMR1+/y and CON2 lines but altered the bursting profile  in FMR1-/y and FXS3 
lines (Fig. 5A-B).  Veratridine significantly reduced the frequency of action potential bursts and increased 
the durations of FMR1-/y and FXS3 lines (Fig. 5C, D).  Thus, to some extent activating voltage-dependent 
Na+ channels in neurons lacking FMRP gave rise to activity that phenocopies that seen in FMR1+/y and 
CON2 lines.    
Neurons lacking FMRP show reduced IBKCa densities and their bursting properties are 
insensitive to paxilline 
A variety of mRNAs encoding potassium channel subunits are targets for FMRP [8, 45].  Moreover, FMRP 
interacts with the auxiliary β4 subunit of the calcium activated potassium channel (BKCa) leading to 
increased activation of this current [31].  Indeed in studies of Fmr1-/y mice the reduced activity of the BKCa 
current (IBKCa) in the pyramidal neurons of hippocampus and cortex can be ameliorated by the genetic 
over-expression of the β4 subunit [32] or by the administration of a BKCa channel activator [46].  Thus, we 
wanted to determine whether in human neurons lacking FMRP there was similarly a reduced density of 
IBKCa.  A depolarizing voltage ramp [32] was applied to neurons and the IBKCa was pharmacologically isolated 
by recording in the absence and presence of a specific BKCa channel blocker, paxilline (Fig. 6A,B).  As 
illustrated in Fig. 6C, D and consistent with previous studies in mice [31] the magnitude of IBKCa was  
significantly reduced in FMR1-/y and FXS3 lines as compared to either FMR1+/y or CON2 lines.  Again, given 
the difference in magnitude of this current in lines expressing FMRP and those lacking FMRP we would 
expect that blocking IBKCa would alter the action potential burst profile of FMR1+/y and CON2 neurons to 
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resemble FMR1-/y or FXS3 neurons.  As illustrated in Fig. 6E, F we confirmed this by showing that paxilline 
(10 µM) increased the number of action potential bursts occurring in a 10 minute recording period in 
FMR1+/y and CON2 neurons but was without effect in FMR1-/y or FXS3 neurons.  Nevertheless, and as 
quantified in Fig. 6G, paxilline did not alter, significantly, the duration of the action potential bursts in 
FMR1+/y and CON2 neurons (or indeed in FMR1-/y or FXS3 neurons).  These results suggest that BKCa 
channels play a critical role in determining action potential burst frequencies in these neurons. Thus, as 
described above we are able to manipulate selectively the firing pattern in a manner that is dependent 
on FMRP expression. 
Discussion 
Descriptions of altered cortical network excitability in FXS patients have been described (reviewed in [11]), 
however, the physiological detail underpinning these observations remain to be explored in a human 
context.  Indeed, current mechanistic understanding of altered excitability is largely based on the 
description of altered network excitability in rodent-based FXS models.  Moreover, while we and others 
exploit the advantages of such models to understand pathophysiology and dysfunction, we must also 
consider that they may not always reflect human-specific physiology.  The temporal profile of FMRP 
express during the process of embryonic development is a critical factor in FXS.  Studies have shown that 
despite CGG-repeat expansion, FMRP can be detected in the human embryonic tissue, until the end of 
the first trimester [47, 48].  This is not seen in genetically engineered rodent models [49, 50] indicating 
that such models that might not recapitulate fully the etiology of FXS in humans.  Thus, the ability to model 
neurodevelopmental diseases using human pluripotent stem cells gives us the opportunity to extend our 
physiological understanding of FXS in a human context.  
For the first time, this study provides mechanistic insight into how loss of FMRP can lead to 
aberrant network activity in human cortical neurons derived from pluripotent stem cells. Three key 
findings emerge from our study.  First, human cortical neurons lacking FMRP displayed spontaneous burst 
firing of action potentials at a greater frequency but with shorter durations compared to human cortical 
neurons.  Second, despite differences in spontaneous firing patterns, we could find no differences in the 
passive and active membrane properties of human cortical neurons lacking FMRP compared to those 
expressing FMRP.  Finally, synaptic activity as assessed by measuring mEPSC amplitudes and frequencies 
showed no differences between FMRP-lacking and FMRP-expressing neurons.  Critically, the difference in 
burst firing can be attributed, unequivocally, to the loss of FMRP expression as the firing properties of 
both iPSC FXS patient-derived cortical neurons were indistinguishable from those recorded in the FMR1-
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/y line, a CRISPR-Cas9 gene-edited ESC line.  Furthermore, each of the lines expressing FMRP (FMR1+/y, 
CON1 and CON2) also displayed firing properties (less frequent but longer bursts) that were 
indistinguishable from each other.  The most parsimonious explanation for these findings is that the loss 
of expression of FMRP is responsible for the differences in the burst firing and not other environmental 
causes or impacts of genetic diversity between non-isogenic pairs. 
The duration of the bursting activity we observed is determined by the temporal nature of the 
synaptic input received by any individual neuron.  This can be concluded as voltage-clamp recordings 
indicated the duration of the synaptic current activity matches that of the action potential bursting activity 
observed in our current-clamp recordings.  In other words, it is not the case, for example, that a similar 
duration period of synaptic activity triggers different duration bursting activity in control and FMRP-
lacking neurons.  Indeed, given the similarities in the active membrane properties of control and FMRP-
lacking neurons it is perhaps unlikely that ‘inputs’ of equivalent duration would result in different duration 
‘outputs’.  Of course, it is a matter of semantics as to whether it is the duration of bursting that drives the 
synaptic event duration or the duration of the synaptic event that drives the membrane depolarization 
and action potential bursting event. 
Spontaneous network properties are influenced by active and passive membrane properties and 
indeed many studies have reported that in rodent models the loss of expression of FMRP leads to cortical 
hyperexcitability [9, 12-14, 36].  It is becoming increasingly clear that FXS pathophysiology as assessed in 
rodent models shows complex diversity.  For example, a recent study using mouse cortical primary 
neurons from Fmr1-/y mice have reported no change in intrinsic and synaptic excitability [15], while 
hypoexcitability has been reported in Fmr1-/y neurons from fetal mouse visual cortex [16].  These exemplar 
studies indicate that the properties of neurons lacking FMRP is dependent of developmental stage and 
neuronal subtype being investigated.  Indeed, in our system intrinsic excitability and synaptic properties 
were unaltered.  Furthermore, the lack of any differences in the passive and active membrane properties 
of FMRP-lacking human cortical neurons and control neurons contrasts with a previous report [21] that 
suggested ESC-derived neurons lacking FMRP were only capable of firing, at most, one action potential 
following a depolarizing current injection.  While there are differences in the protocols used to generate 
pluripotent stem cell-derived neurons between these studies our data do not support the notion that the 
human cortical neurons lacking FMRP generated using our culture protocols are hypoexcitable.  
Moreover, our data while showing variability in the maximum number of action potentials produced 
following current injection, do not indicate that control and FMRP-lacking cortical neurons respond 
differently.  Indeed, in all the parameters we have assessed no significant differences were observed 
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across any of the lines examined.  Specifically, in regard to the maximum number of action potentials 
elicited by depolarizing current injections, while we do observe cells (irrespective of genotype) which only 
responded with a single action potential, the majority give rise to multiple action potentials during the 
depolarizing step.  Analysis of synaptic function as assessed by measuring the properties of mEPSCs 
indicated that their frequencies and amplitude were not different between genotypes.  This finding is in 
contrast to the studies on embryonic FXS stem cells that have reported decreased frequencies of 
spontaneous glutamatergic synaptic currents [20, 21]. 
  FMRP has numerous target mRNAs that encode synaptically-located proteins and more 
specifically that encode proteins associated with ion channels or their regulation [8].  Studies investigating 
prefrontal and entorhinal cortical neuron dysfunction in Fmr1-/y mice concluded that the hyperexcitability 
displayed by these neurons was due to an increase in transient [38] and persistent [30] sodium currents.  
Our data show that in human neurons lacking FMRP there is very little expression of the persistent sodium 
current and application of riluzole did not alter the profile of action potential bursting in these neurons.  
However, in control neurons, riluzole significantly reduced the duration of action potential bursts without 
affecting their overall frequency.  This is in contrast to the observations seen in mouse models, whether 
this difference in the role of the persistent sodium current reflects a difference between human and 
mouse model systems or is a reflection of, for example, a more immature developmental stage of the 
human neurons used is not clear.  Nevertheless, pharmacological activation of voltage-dependent sodium 
channels, by veratridine, in FMRP-lacking human cortical neurons resulted in a bursting profile that was 
very similar to that seen in control neurons.  Moreover, veratridine had no effect on control neurons, 
possibly indicating that increasing voltage-dependent sodium channel activity in FMRP-null neurons can 
restore a bursting profile that is equivalent to that seen when FMRP is expressed.   
FMRP modulates a number of potassium channels [8] and of specific interest for our present study 
is its regulation of large conductance calcium-activated potassium channels [45, 51, 52] where absence of 
FMRP results in lower current densities [31, 32, 46].  Indeed over-expression of the auxiliary β4 subunit 
has been shown to reduce cellular and circuit dysfunction [32] or activation of this conductance rescues 
sensory hypersensitivity and dendritic hyperexcitability [46] in Fmr1-/y mice.  In agreement with these 
rodent-based FXS models we observed that human cortical neurons lacking FMRP had lower densities of 
large conductance calcium-activated potassium currents.  Furthermore, blocking these channels with 
paxilline resulted in an alteration in the action potential bursting profile only in the control lines and was 
without effect in FMRP-null lines that suggests that the bursting profile seen in human FMRP-null neurons 
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may also have an origin in dysregulated large conductance calcium-activated potassium channel 
expression.     
In summary, our study demonstrates that in human cortical neurons loss of FMRP results in an 
aberrant action potential bursting profile when compared to control neurons.  This does not result from 
altered intrinsic and synaptic excitability but rather propose that this altered activity results from reduced 
NaP and BKCa conductances.  While reduced BKCa conductance has been reported in rodent models it is 
important to highlight that our finding of reduced NaP conductance contrasts with studies that have 
utilized rodent models.  
Limitations 
Increased burst frequency has been reported in mouse Fmr1-/y somatosensory cortical neurons 
[12] and Fmr1-/y neurons in mouse cortical primary cultures [53].  However, the vast majority of neurons 
in our cultures are glutamatergic since there are no GABAergic interneurons, as assessed by staining for 
GAD [27-29].  As such the properties of the network activity we recorded in our conditions are not 
equivalent to those recorded in rodent-based FXS models that have utilized either in vitro cultures, ex vivo 
slice preparations or in vivo recording; such preparations will contain a variety of subpopulations of 
inhibitory interneurons [9, 10, 12-15, 30-32, 36, 37, 53].    Thus, direct comparisons of the type of network 
activity we have recorded are not necessarily prudent.  However, it is interesting to note that a recent 
study using human iPSC-derived neurons and using extracellular multi-electrode array recordings 
reported an increase in spontaneous firing rate in FMRP-lacking neurons although no direct assessment 
of the profiles of action potential bursting was performed [23].   Notwithstanding these caveats, our study 
for the first time shows the robustness of the difference in the profile of activity observed in our control 
and FMRP-lacking human cortical neurons. This can be exploited to gain insight into the potential 
mechanistic basis for their distinct activity patterns.  We also note that each of the lines display passive 
and active membrane properties (relatively depolarized resting membrane potentials, high input 
resistances, broad action potential half-widths and relatively low estimates of membrane capacitance) 
that are consistent with these neurons still being considered to be developmentally immature; again this 
is consistent with our previous studies where we have investigated the physiological properties of human 
pluripotent stem cell-derived neurons [27-29, 54, 55]. 
Conclusion 
We conclude that pharmacological manipulations can alter the action potentials burst profiles in 
both control and FMRP-null human cortical neurons, making them appear like their genetic counterpart.  
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Our studies indicate that FMRP targets which have been found in rodent models of FXS are also potential 
targets in this human-based model system.  Indeed, given the very distinct profiles of activity in the control 
and FMRP-null lines it is advantageous to consider using an assessment of this activity as a surrogate for 
neuronal network activity in a human-based model system.  Such studies complement research that use 
a variety of animal models, the latter having the advantage that many more types of investigation can be 
performed that cannot be carried out in a human-based system.  Ultimately, the goal of our studies and 
those of others using pluripotent stem cell derived neural tissue should be to gain better mechanistic 
insights into the dysfunction caused by loss of FMRP expression.  This will hopefully allow new potential 
therapeutics to be assessed in an array of pre-clinical platforms that may result in greater translation to 
the clinic. 
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Supplementary Information 
Additional File. Figure S1.  Active and passive membrane properties of human pluripotent stem cell derived 
cortical neurons lacking FMRP are similar to the control neurons.  
(A) Representative current-clamp traces showing action potential firing in response to two depolarizing 
current injections (500 ms; +15 pA or +30 pA) from either FMR1+/y (black trace) or FMR1/-y (red trace) 
neurons.  (B, C, D, E) Quantification of the passive membrane properties of hESC (FMR1+/y, FMR1-/y) and 
hiPSC (CON1, CON2, FXS1, FXS2, FXS3) derived cortical neurons illustrating no significant differences 
between control neurons and neurons lacking FMRP in their resting membrane potential (B), input 
resistance (C), capacitance (D) or rheobase current (E).   (F, G, H, I) Quantification of action potential 
parameters in each of the lines indicating no difference in action potential (AP) threshold (F), AP amplitude 
(G), AP half-width (H) or the maximum number of APs fired in response to depolarizing current injections 
(I).  One-way ANOVA with post hoc Tukey’s test. FMR1+/y: n = 19, N = 3; FMR1-/y: n = 15, N = 3; CON1: n = 
25, N = 3; CON2: n = 18, N = 3; FXS1: n = 19, N = 3; FXS2: n = 33, N = 3; FXS3: n = 21, N = 3.  
Additional File. Figure S2.  Synaptic activity of human cortical neurons lacking FMRP is comparable to the 
control neurons.  
(A) Representative voltage-clamp traces of mEPSCs (Vhold = –70mV) from either FMR1+/y (black) and FMR1-
/y (red) neurons and recorded in the presence of TTX (500 nM). (B) As in (A) but from CON1 (black) or FXS1 
(red) neurons.  (C) Quantification of mEPSC frequencies indicating that these do not differ between each 
of the lines examined and had mean values of 0.443 ± 0.10 Hz (FMR1+/y; n = 10, N = 2); 0.403 ± 0.11 Hz 
(FMR1-/y; n =10, N = 2); 0.96 ± 0.18 Hz (CON1; n =23, N =3) and 0.78 ± 0.11 Hz (FXS1, n = 20, N = 3).  (D) 
Quantification of mEPSC amplitudes indicating that these do not differ between each of the lines 
examined and had mean values of 20.85 ± 3.13 pA (FMR1+/y); 20.72 ± 3.08 pA (FMR1-/y); 26.3 ± 2.53 pA 
(CON1) and 29.92 ± 3.54 pA (FXS1).  One-way ANOVA with post hoc Tukey’s test.   
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Figure Legends 
Figure 1. Specification of neurons from human stem cell and pluripotent stem cell derived neural progenitor 
cells. 
(A) LI-COR immunoblot image of FMRP obtained from each of the pluripotent stem cell lines examined.  
The image illustrates that FMR1+/y, CON1, CON2 cell lines express FMRP (71 kDa) and FMR1-/y, FXS1, FXS2 
and FXS3 lines lack FMRP. Rat brain lysate from Fmr+/y and Fmr1-/y animals were used as positive and 
negative controls respectively. (B) Left panel: Representative confocal images of paraformaldehyde fixed 
hESC (FMR1+/y and FMR1-/y) and hiPSC (CON2 and FXS3) expressing the pluripotency markers, Nanog and 
Oct3/4. Scale bar = 50 µm. Middle panel: Immunofluorescent staining of NPCs arranged as rosettes 
(derived from either hESC and hiPSC) for the progenitor markers Nestin and PAX6. Scale bar = 50 µm. 
Right panel: Confocal images illustrating hESC and hiPSC derived cortical neurons expressing 
Map2ab/DAPI/hNA.  The GFAP positive cells are murine astrocytes (negative for human nuclei) with which 
hESC- and hiPSC-derived neurons were co-cultured.  Scale bar = 50 µm. Abbreviations: hESC: human 
embryonic stem cells; hiPSC: human pluripotent stem cells; FMR1+/y: human embryonic stem cell line. 
FMR1-/y: gene edited isogenic hESC pair lacking FMR1 gene. L: Ladder. CON1; CON2: control hiPSC line.  
FXS1, FXS2 and FXS3: hiPSC lines from fragile X syndrome patients. 
Figure 2. Bursts of action potentials occur at high frequencies but with shorter durations in neurons lacking 
FMRP. 
(A) Representative current-clamp recording (Vhold = –70mV) of spontaneous bursts from either FMR1+/y 
(black) or FMR1-/y (red) neuron illustrating the difference in action potential bursting profiles. (B) As in (A) 
but illustration recordings fron hiPSCs lines CON1 (black) and FXS1 (red).  (C) Mean burst number per 10 
minutes of recording for each of the hESC and hiPSC lines.  Overall the mean number for bursts (per 10 
minutes) are: 5 ± 0.65 (FMR1+/y; n = 16, N = 3);  22.53 ± 2.63 (FMR1-/y; n = 15, N = 3); 3.9 ± 0.81 (CON1; n 
=20, N = 3); 7.727 ± 0.88 (CON2; n = 22, N = 3); 28.07 ± 3.73 (FXS1; n = 13, N = 3); 17.74 ± 2.10 (FXS2; n = 
19, N = 3);  25.71 ± 3.56 (FXS3; n = 21, N = 3).  (D) Mean burst duration for each of the hESC and hiPSC 
lines.  Overall the mean durations are: 50.4228 ± 2.88 s (FMR1+/y);  12.85 ± 0.92 s (FMR1-/y); 54.15 ± 7.03 
s (CON1); 47.38 ± 4.30 s (CON2); 11.66 ± 1.51 s (FXS1); 25.25 ± 2.1 s (FXS2); 18.55 ± 2.58 s (FXS3).  ***p< 
0.001, one way ANOVA with post hoc Tukey’s test. 
Figure 3. Neurons lacking FMRP display bouts of inward current activity of higher frequencies but of shorter 
durations compared to control neurons. 
(A) Representative voltage-clamp recording (Vhold = –70mV) of spontaneous inward currents from either 
FMR1+/y (black) or FMR1-/y (red) neurons illustrating the difference in spontaneous events. The insets 
below each trace illustrate an expanded time-base where evidence of synaptic currents underlying these 
inward currents can be observed. (B) As in (A) but illustration recordings from hiPSCs lines CON1 (black) 
and FXS1 (red).  (C) The number of events is higher in neurons lacking FMR1 than control. Overall the 
mean number for bursts (per 10 minutes) are: 4.5 ± 0.56 (FMR1+/y; n = 8, N = 3); 20.67 ± 3.96 (FMR1-/y; n 
= 12, N = 3); 2.8 ± 0.34 (CON1; n =13, N = 3); 23.85 ± 2.92 (FXS1; n = 11, N = 3).  (D) Mean burst durations 
recorded from neurons lacking FMRP are shorter than those from control lines.  Overall the mean 
durations are: 40.72 ± 6.8 s (FMR1+/y); 9.28 ± 1.05 s (FMR1-/y); 59.90 ± 9.07 s (CON1); 11.52 ± 1.55 s (FXS1).  
***p< 0.001, paired t-test, Wilcoxon test.  
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Figure 4.  Neurons lacking FMRP have reduced INaP densities and their burst properties are insensitive to 
riluzole. 
(A) Persistent sodium currents (INaP) evoked by a slow depolarizing ramp (−100 mV to −20 mV, 20 mV/s) 
either before (traces a) or during (traces b) application of TTX. The TTX-sensitive current (traces c) was 
isolated by subtracting traces a and b. (B) I-V curves plotted from the ramp-evoked INaP, showing the 
decreased INaP in neurons lacking FMRP. Currents are normalized to the corresponding cell capacitance. 
(C) Quantification of current density at −20 mV show significant decrease of the persistent sodium current 
in neurons lacking FMRP.  Overall mean current densities are: -1.44 ± 0.17 (FMR1+/y, n = 18, N=3); -1.73 ± 
0.33 (CON2, n = 10, N =3); -0.27 ± 0.03 (FMR1-/y, n = 18, N=3); -0.35 ± 0.098 (FXS3, n = 9, N = 3).  **p< 0.01, 
***p< 0.001, two-way repeated measures ANOVA with post hoc Tukey’s test, paired t-test, Wilcoxon test.  
(D) Representative traces illustrating spontaneous bursts recorded from either a FMR1+/y neuron or a 
FMR1-/y neuron before and after the application of riluzole (0.1 µM).  (E) Quantification of the number of 
bursts recorded from FMR1+/y , CON2, FMR1-/y or FXS3 neurons before (open symbols) or after (closed 
symbols) application of riluzole.  Overall the mean number of bursts recorded are: 5.733 ± 0.72 (FMR1+/y, 
n = 15, N= 3); 5.733 ± 0.65 (FMR1+/y + riluzole, n= 15, N=3); 6.3 ± 0.9 (CON2, n=10, N=3); 7 ± 1.12 (CON2 + 
riluzole, n=10, N=3); 42.33 ± 8.92 (FMR1-/y , n = 9, N=3);  38.89 ± 8.49 (FMR1+/y + riluzole, n=9, N=3); 34.1 
± 9.52 (FXS3, n=10, N=3); 34.3 ± 9.62 (FXS3 + riluzole, n=10, N=3).  (F) Quantification of the duration of 
bursts recorded from FMR1+/y , CON2, FMR1-/y or FXS3 neurons before (open symbols) or after (closed 
symbols) application of riluzole. Overall the mean burst durations are: 47.86 ± 6.27 s (FMR1+/y); 14.14 ± 
1.33 s (FMR1+/y + riluzole); 47.81 ± 12.14 s (CON2); 25.55 ± 9.54 s (CON2 + riluzole); 8.77 ± 1.34 s (FMR1-/y 
);  9.43 ± 1.62 s (FMR1+/y); 8.91 ± 2.19 s (FXS3); 9.01 ± 2.52 (FXS3 + riluzole) **p< 0.01; ***p< 0.001, paired 
t-test, Wilcoxon test. 
 
Figure 5. In neurons lacking FMRP activation of voltage-dependent Na+ channels decreases action potential 
burst frequencies but increases their duration. 
(A) Representative traces of a FMR1+/y neuron illustrating spontaneous action potential bursting before 
and after the application of veratridine (0.5 µM). (B) As in (A) but illustrating traces obtained from a FMR1-
/y neuron. (C)  Quantification of burst number in FMR1+/y, CON2, FMR1-/y and FXS3 lines before and after 
the application of veratridine.  Veratridine reduced significantly the frequency of bursts in lines lacking 
FMRP.  Overall the mean number of bursts are: 6 ± 0.92 (FMR1+/y, n = 10, N= 3); 7.3 ± 0.76 (FMR1+/y + 
veratridine, n= 10, N=3); 7.87 ± 1.46 (CON2, n=8, N=3); 8 ± 1.45 (CON2 + veratridine, n=8, N=3); 39.29 ± 
5.27 (FMR1-/y , n = 14, N=3);  8.857 ± 0.98 (FMR1+/y + veratridine, n=14, N=3); 24.45 ± 4.37 (FXS3, n=11, 
N=3); 7.818 ± 1.32 (FXS3 + veratridine, n=11, N=3)  (D)  Quantification of action potential burst durations 
in each of the four lines examined.  Veratridine increased significantly the duration of bursts in FMR1-/y 
and FXS3 lines and had no overall effect on FMR1+/y and CON2 lines.  Overall the mean burst durations 
are: 39.09 ± 6.47 s (FMR1+/y); 34.34 ± 4.5 s (FMR1+/y + veratridine); 37.42 ± 7.39 s (CON2); 35.77 ± 7.25 s 
(CON2); 7.318 ± 0.64 s (FMR1-/y );  25.5 ± 3.23 s (FMR1+/y + veratridine); 7.004 ± 1.28 s (FXS3); 32.26 ± 5.66 
(FXS3 + veratridine). For both (C) and (D) **p< 0.01, ***p< 0.001, paired t-test, Wilcoxon test.  
Figure 6. Neurons lacking FMRP have reduced IBKCa densities and their burst properties are insensitive to 
paxilline. 
(A) Large Ca-activated potassium currents (IBKCa) evoked by a depolarizing voltage ramp from −110 mV to 
+40 mV, 10 mV/s, with a hold of 50ms at +40 mV.  (B) The IBKCa was isolated by subtracting the currents 
recorded in the absence and presence of paxilline (10 µM). (C) I-V curves plotted from the ramp-evoked 
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IBKCa showing the decreased IBKCa in neurons lacking FMRP.  Currents are normalized to the corresponding 
cell capacitance. (D) Quantification of current densities at +40 mV show significant decrease of IBKCa in 
neurons lacking FMRP. Overall mean current densities are: 11.73 ± 1.49 (FMR1+/y, n = 15, N=3); 7.4 ± 1.43 
(CON2, n = 14, N =3); 3.57 ± 0.62 (FMR1-/y, n = 14, N=3); 1.44 ± 0.78 (FXS3, n = 12, N = 3).   *p< 0.05, ***p< 
0.001, two-way repeated measures ANOVA with post hoc Tukey’s test, paired t-test, Wilcoxon test.   (E) 
Representative traces illustrating spontaneous bursts recorded from either a FMR1+/y neuron or a FMR1-
/y neuron before and after the application of paxilline (10 µM) and illustrating the increase of action 
potential burst frequencies in FMR1+/y neurons in the presence of paxilline.  (F) Quantification of the 
number of bursts recorded from FMR1+/y , CON2, FMR1-/y or FXS3 neurons before (open symbols) or after 
(closed symbols) application of paxilline.   Overall mean number of bursts are: : 6.7 ± 1.086 (FMR1+/y, n = 
10, N= 3); 13.8 ± 1.85 (FMR1+/y + paxilline, n= 10, N=3); 5.6 ± 1.08 (CON2, n=10, N=3); 11.3 ± 1.94 (CON2 + 
paxilline, n=10, N=3); 25.5 ± 4.51 (FMR1-/y , n = 10, N=3);  26 ± 5.12 (FMR1+/y + paxilline, n=10, N=3); 25.4 
± 6.6 (FXS3, n=10, N=3); 26.5 ± 5.95 (FXS3 + paxilline, n=10, N=3). (G) Quantification of the duration of 
bursts recorded from FMR1+/y , CON2, FMR1-/y or FXS3 neurons before (open symbols) or after (closed 
symbols) application of paxilline. Overall mean burst duration are: 40.97 ± 8.68 s (FMR1+/y); 38.47 ± 7.85 
s (FMR1+/y + paxilline); 58.65 ± 13.12 s (CON2); 56.08 ± 14.04 s (CON2 + paxilline); 2.65 ± 0.53 s (FMR1-/y );  
3.08 ± 0.68 s (FMR1+/y + paxilline); 4.107 ± 0.64 s (FXS3); 3.93 ± 0.77 (FXS3 + paxilline).   **p< 0.01, ***p< 
0.001, paired t-test, Wilcoxon test. 
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